Puma Biotechnology Inc. (NYSE:PBYI)

CAPS Rating: 1 out of 5

Results 1 - 7 of 7

Recs

0
Member Avatar YourDailyBear (60.21) Submitted: 1/14/2016 1:28:07 PM : Underperform Start Price: $49.32 PBYI Score: +17.29

Puma has 0 Revenue and a $1.57 Billion market cap. Crazy overvalued and bearish trend.

Recs

0
Member Avatar IWantToBeatBabo (94.83) Submitted: 11/19/2015 11:49:48 AM : Underperform Start Price: $67.44 PBYI Score: +31.26

Now that I have down thumbed it Puma will probably announce next week they are being acquired by Lilly or Merck in a buyout valued at an 80% premium to the current market price!

Recs

0
Member Avatar 1russianguy (< 20) Submitted: 8/20/2015 3:29:53 PM : Outperform Start Price: $88.32 PBYI Score: -48.20

Playing for a bounce from a correction.

Recs

0
Member Avatar TMFTypeoh (74.44) Submitted: 6/24/2015 11:57:47 AM : Outperform Start Price: $124.55 PBYI Score: -57.09

Pullback could be a decent entry point. Strong inside ownership.

Recs

0
Member Avatar CramersSkeeDaddy (98.35) Submitted: 7/23/2014 2:04:00 PM : Underperform Start Price: $232.10 PBYI Score: +77.48

up 300% in one day, enough said. Hopefully they do cure/treat all cancer but the short squeeze will likely end soon. No or little revenue, or earnings.

Recs

0
Member Avatar dabhsar (< 20) Submitted: 6/2/2013 8:56:29 AM : Outperform Start Price: $39.55 PBYI Score: -14.29

This small Bio Tech company is onto key medicine break through.

Recs

0
Member Avatar IBDContrarian (54.39) Submitted: 4/6/2013 1:50:39 PM : Underperform Start Price: $30.95 PBYI Score: -7.29

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MEDICAL 1 96 -- A- NO EARN

Results 1 - 7 of 7

Featured Broker Partners